Going from macro to micro, Timothy McGrath has taken the reins as CEO of Houston microarray startup Xeotron: McGrath was for the past eleven years president of the Sigma-Genosys subsidiary of chemical giant Sigma-Aldrich. McGrath also has previously held positions in sales and marketing at Millipore, Zymark, and Beckman Instruments. McGrath said in a statement that he thought the company’s XeoChip microarray, which it is beginning to ship, was “compelling and enabling in a market segment that is large and growing.”
Affymetrix CEO and chairman Stephen Fodor and Cambridge University medical genetics professor John Todd have taken seats on scientific advisory board of Phenomix, a San Diego drug discovery genomics startup. Phenomix, which focuses on what it calls “forward genomics,” is the exclusive license holder for a trove of technology from the Genomics Institute of the Novartis Research Foundation, the Medical Genome Center of the John Curtin School of Medical Research at the Australian National University in Canberra, Australia, and the Department of Genetics at Baylor College of Medicine. Fodor will provide his expertise on technology development to the company, while Todd, an expert in the genetics of type 1 diabetes, will provide his disease-genetics knowledge.
Fodor, who has led Affymetrix since its spinoff from parent Affymax, also is stepping into run Affymetrix day-to day in the near-term, while president Sue Siegel takes a leave of absence due to health issues, the company said.